Why CSG’s Stock Keeps Falling Even as NATO Orders Flow and Capacity Doubles

The Czechoslovak Group (CSG) is doing everything a defense contractor should do to win over the market: signing fresh NATO contracts, deepening control over critical munitions components, expanding production capacity in Ukraine, and delivering a 13.8% revenue jump. Yet none of it is enough. The stock closed at €15.05 on Friday, down 3.58% on the day and 16.68% over the past seven sessions. From its January high of €36.05, the shares have cratered 58.26%.

The contradiction is stark. CSG’s first-quarter numbers were robust — revenue of €1.544 billion, operating EBIT of €372 million (up 8.7%), and an order backlog that swelled 15.1% to €17 billion. Pipeline negotiations total €27 billion. Management confirmed full-year guidance of €7.4 to €7.6 billion in sales and an operating margin around 24-25%. Operationally, the story is one of momentum.

So why is the market running in the opposite direction? The answer lies not in the data but in the trust deficit that has attached itself to the stock — a combination of a bruising shareholder dispute, a short-seller attack, and a governance fog that no amount of production ramp-ups can seem to clear.

New Orders, New Ventures — But No New Buyers

On 3 June, CSG unveiled two significant contracts for mechanical and electronic fuzes for large-caliber ammunition. The value is in the high double-digit millions of euros, with deliveries to European NATO customers beginning this year. The electronic fuze work will be channeled through Fuchs Electronics Europe, a newly created joint venture between CSG and South Africa’s Reunert, to be based in Slovakia. The move is a clear attempt to insulate the group from external supply-chain volatility.

Should investors sell immediately? Or is it worth buying CSG?

That vertical integration push goes further. On 2 June, CSG disclosed it holds 9.9% of the voting rights in Alzchem, a producer of nitrocellulose — a critical ingredient in propellant charges for artillery munitions. Via financial instruments, CSG can access another 10.2%, giving it aggregate control of roughly 20.1%. The logic is straightforward: owning the raw materials for munitions stabilizes margins and shields production schedules in a market where supply chains remain stretched.

In Ukraine, CSG has licensed production of large-caliber ammunition through partner Ukrainian Armor. The technology transfer is complete, with an initial target of 100,000 rounds of 155 mm ammunition per year, plus 50,000 rounds of 105 mm. The company’s own production capacity for large-caliber rounds exceeded 800,000 units at the end of the first quarter and is expected to reach 850,000 by year-end, with an additional 400,000 from reactivated capacity.

The Governance Cloud That Won’t Lift

Against this backdrop of expansion, the stock has been hammered by two related developments. First, Hunterbrook Media published allegations that led to the disclosure of a short position by its affiliated investment vehicle Hunterbrook Capital. CSG has rejected the claims.

Second, the dispute with minority investor Petr Kratochvíl has escalated into full-blown litigation. Kratochvíl holds 10% of CSG Land Systems CZ and roughly 9% of the MSM Group. He is demanding about 35 billion Czech crowns for his stakes; majority shareholder Michal Strnad is offering 4 billion. The gap of 31 billion crowns has stalled negotiations, and courts in both the Czech Republic and Slovakia are now involved. Kratochvíl was removed as chairman in March on conflict-of-interest grounds and has since challenged not only the valuation of his stakes but also certain share transfers within the MSM Group since the start of 2026.

For investors, the legal overhang creates a layer of uncertainty that operational metrics cannot easily offset. The market is pricing in the risk of further governance costs and ownership instability, not just the order flow.

CSG at a turning point? This analysis reveals what investors need to know now.

Technicals Paint a Bleak Picture

The share price is now 23.44% below its 50-day moving average of €19.66 (using primary article figure; note secondary mentions €19.66 as well). The relative strength index sits at 32.0, just shy of oversold territory but sliding fast. Attempts at recovery have been fleeting: in Prague, the stock rose 1.01% on Thursday to 381.8 crowns, but that bounce reversed in euro trading the same day. Friday’s drop confirmed that any rally is being sold into.

Analysts remain uniformly bullish. All ten covering the stock rate it a buy, with price targets ranging from €25 to €42 and a consensus of €32.45 — more than double the current price. That gap between analyst conviction and market reality underscores just how deep the trust discount has become.

What’s Next

CSG will report first-half results on 7 August 2026. That date will provide the next hard test: a chance to show that the operational engine can overcome the governance drag. Until then, the stock is caught between a defense boom it should be benefiting from and a narrative that has shifted from fundamentals to fear.

Ad

CSG Stock: New Analysis - 6 June

Fresh CSG information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated CSG analysis...

en | NL0015073TS8 | WHY | boerse | 69490782 |